KeyBanc reiterates Lonza stock rating on strong modality positioning By Investing.com

KeyBanc reiterated an Overweight rating and CHF665 price target on Lonza Group, citing strong trends across antibodies, ADCs, CGT, and small molecule modalities. The firm pointed to Lonza’s 11%-12% constant-currency CDMO growth guidance for FY2026 and argued actual growth could exceed that, supported by the ongoing divestiture of 60% of Capsules & Health Ingredients. The note is supportive for sentiment but is likely to have limited near-term market impact beyond the shares.

Analysis

The market is likely underestimating how much of Lonza’s earnings quality improves once it is more purely a high-margin biologics platform rather than a mixed portfolio with a lower-multiple consumer/ingredients drag. That matters because the rerating is not just about growth; it is about duration of growth, which supports a materially higher terminal multiple if management executes on capacity and mix. The key second-order effect is that CDMO bottlenecks in complex modalities can push sponsors to prioritize secure manufacturing slots earlier, reinforcing Lonza’s pricing power beyond the current cycle.

The real upside lever is not the FY2026 guide itself, but the probability that guidance proves conservative if pipeline conversion in ADCs and cell/gene therapy continues to broaden. In high-complexity manufacturing, incremental volume tends to be disproportionately accretive once fixed assets are in place, so even modest demand beats can translate into outsized EBITDA revisions over 12–24 months. That creates a setup where the stock can compound through both multiple expansion and estimate revisions, especially as the divestiture removes an overhang around strategic focus.

The main risk is execution, not demand: any delay in separation, remediation of manufacturing issues, or capex creep would hit the stock more than a simple growth miss because the name is priced as a quality compounder. Also, the valuation already embeds a lot of optimism, so a 1–2 quarter pause in order conversion could compress the multiple quickly. The contrarian angle is that investors may be paying for the normalization of a ‘best-in-class’ scarcity premium before the company has fully proven the post-divestiture margin structure.

From a positioning standpoint, this is better expressed as a relative-quality long than an outright momentum chase. The trade works if the market continues to reward visibility in complex biologics and penalize lower-quality healthcare manufacturing names with less pricing power and shorter growth duration.

Key Decisions for Investors

• Go long LONN/LZAGY on a 6-12 month horizon; add on any post-guidance pullback of 5-8% because the better risk/reward is in buying execution concerns, not strength.
• Pair trade: long LONN vs short a lower-quality CDMO/health ingredients peer basket for 3-6 months; thesis is multiple expansion from focus and mix shift, not just sector beta.
• Buy medium-dated call spreads on LONN if implied volatility is reasonable; this captures rerating upside while defining risk around separation/execution delays.
• Take profits if the stock re-rates to a premium that implies flawless execution before the divestiture closes; the asymmetry deteriorates once the market fully prices in the 2026 growth story.